As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...

Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC ...

ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.

ASHEVILLE — After going 9-4 and reaching the third round of the NCHSAA playoffs last season, Reynolds football retooled its offense. The Rockets added IMG Academy junior transfer quarterback Ely ...

Tokyo Electric Power Company has suspended the first attempt to extract fuel debris from within the primary containment vessel of unit 2 at the damaged Fukushima ...

(RTTNews) - Merck & Co., Inc. (MRK) and Daiichi ... small cell lung cancer or ES-SCLC. According to the companies, an objective response rate of 54.8% was observed with Daiichi Sankyo and Merck's ...

Merck (NYSE:MRK) and Daiichi Sankyo (OTCPK:DSNKY) (OTCPK:DSKYF) on Saturday announced interim results from a Phase 2 trial for lung cancer patients treated with ifinatamab deruxtecan (I-DXd ...

DURHAM – Nick Reynolds’ rookie season has an extremely impressive resume. State champion. State record holder. Now, he can add New England champion to that list. Reynolds, a Concord High ...

Based on three phase 2 trials of Daiichi Sankyo and AstraZeneca (NASDAQ:AZN)'s ENHERTU that showed clinically meaningful responses across a broad range of tumorsENHERTU now has... BASKING RIDGE ...